Table I.
Baseline characteristics among the entire study population and among subgroups defined by NYHA symptom class
| All (N = 2763) | NYHA class II (n = 1867) | NYHA class III (n = 896) | P value* | |
|---|---|---|---|---|
| ICD treatment | 1435 (51.9) | 951 (50.9) | 484 (54.0) | .14 |
| Age (y), mean (SD) | 60.19 (11.8) | 59.74 (11.7) | 61.15 (11.9) | .004 |
| Male sex | 2169 (78.5) | 1492 (79.9) | 677 (75.6) | .01 |
| Race | .622 | |||
| Black | 462 (16.7) | 310 (16.6) | 152 (17.0) | |
| White | 2162 (78.3) | 1468 (78.6) | 694 (77.5) | |
| Other | 139 (5.0) | 89 (4.8) | 50 (5.6) | |
| Ischemic cardiomyopathy | 1613 (58.4) | 1032 (55.3) | 581 (64.8) | <.001 |
| Hypertension | 1314 (54.7) | 847 (52.8) | 467 (58.5) | .01 |
| Diabetes | 848 (30.7) | 531 (28.5) | 317 (35.4) | <.001 |
| Hyperlipidemia | 38 (40.0) | 29 (40.9) | 9 (37.5) | .962 |
| LVEF, mean (SD) | 23.21 (6.6) | 23.66 (6.4) | 22.26 (6.7) | <.001 |
| Prior CABG | 889 (37.0) | 568 (35.4) | 321 (40.1) | .027 |
| Prior MI | 1491 (54.0) | 950 (50.9) | 541 (60.4) | <.001 |
| Prior PCI | 662 (27.6) | 420 (26.3) | 242 (30.3) | .041 |
| LBBB | 504 (21.4) | 336 (21.3) | 168 (21.7) | .885 |
| QRS duration (ms), mean (SD) | 120.10 (31.3) | 118.86 (31.1) | 122.66 (31.6) | .003 |
| Antiarrhythmic drug | 80 (2.9) | 52 (2.8) | 28 (3.1) | .706 |
| β-Blocker | 1854 (67.1) | 1311 (70.2) | 543 (60.6) | <.001 |
| ACE inhibitor | 2450 (88.7) | 1664 (89.1) | 786 (87.7) | .305 |
| GFR* (mL/min/1.73 m2) | <.001 | |||
| ≥60 | 1508 (63.2) | 1082 (68.0) | 426 (53.7) | |
| <60 to ≥30 | 793 (33.2) | 472 (29.7) | 321 (40.4) | |
| <30 | 85 (3.6) | 38 (2.4) | 47 (5.9) | |
| AF | 195 (9.8) | 118 (8.5) | 77 (13.0) | .003 |
| Peripheral vascular disease | 373 (18.8) | 23 (6.6) | 7 (5.4) | .789 |
| Pulmonary disease | 377 (18.1) | 225 (16.2) | 148 (25.0) | <.001 |
| Smoking | 2177 (79.2) | 1478 (79.7) | 699 (78.3) | .425 |
CABG, Coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention; LBBB, left bundle-branch block; GFR, glomerular filtration rate (measured by Chronic Kidney Disease Epidemiology Collaboration formula).
*
Comparison limited to trials with available data.
ICD implantation and sudden versus nonsudden death